Project Context

You are the program lead at HelioGen Bio, a mid-size biotech running 18 concurrent clinical studies across the US and EU. The company’s R&D organization generates regulated data (assay results, sample chain-of-custody, protocol deviations, and analyst sign-offs) that currently lives in a mix of paper binders, shared drives, and a legacy on-prem LIMS. HelioGen is preparing for a Phase 3 pivotal trial and expects an FDA inspection within the next 6–9 months.

To reduce inspection risk and speed up study closeout, the VP of Quality has mandated a move to a new cloud-based platform called Atlas eRecords, which will become the system of record for regulated electronic records and electronic signatures. Atlas is already used for non-regulated collaboration, but it is not yet validated for GxP use and does not currently meet 21 CFR Part 11 expectations (audit trails, e-signatures, record retention, access controls, and validation documentation).

You have 120 days to deliver a Part 11-ready release that supports two high-impact workflows: (1) analytical result approval (scientist → reviewer → QA) and (2) deviation/CAPA approvals. The cross-functional team includes 7 software engineers (4 backend, 2 frontend, 1 SRE), 1 product designer, 2 QA/validation engineers, 1 security engineer (50% allocated), 2 quality/compliance SMEs, and 1 clinical operations lead. The business stakes are high: a failed inspection could delay the Phase 3 program, costing an estimated $8–12M/month in burn and opportunity cost.

Stakeholder Landscape (Competing Priorities)

• VP of Quality (Executive Sponsor): Wants demonstrable Part 11 compliance and validation evidence. Prefers delaying launch over compliance gaps.
• Head of R&D Informatics (Platform Owner): Wants rapid adoption and minimal process friction for scientists; worries that strict controls will reduce productivity.
• Clinical Operations Director: Needs the system live for two studies starting in 10 weeks; cannot tolerate downtime or data loss.
• Security & IT: Focused on identity, access governance, and incident response; concerned about cloud misconfiguration and vendor risk.
• Finance/Procurement: Vendor contract is signed, but there is limited budget for additional tooling and external validation support.

Constraints

1. Timeline: 120 days to production launch for two regulated workflows.
2. No downtime: The legacy LIMS must remain operational; migration must be incremental with zero disruption to ongoing studies.
3. Budget: Only $150K available for external support (e.g., validation consultant, penetration test, tooling).
4. Vendor limitations: Atlas eRecords provides a generic audit log, but it is not immutable by default and does not natively support meaningful e-signature manifestation on exported PDFs.
5. Data retention: Records must be retained for at least 10 years with retrieval SLAs for audits (internal expectation: <24 hours).
6. Access model: Users include internal employees and CRO partners; identity is split between Okta (employees) and federated SSO for partners.

What You Need To Deliver (Candidate Outputs)

Provide a complete execution plan that includes:

1. A Part 11 gap assessment and scope boundary: what is in-scope for this release vs. explicitly deferred, and why.
2. A validation and documentation plan aligned to Part 11 expectations (e.g., risk-based validation approach, traceability, test evidence, SOP updates).
3. A launch plan (phased rollout, training, change management, cutover strategy, rollback plan).
4. A stakeholder alignment strategy including how you will handle conflicting priorities (Quality vs. R&D speed vs. Clinical timelines).
5. Success criteria and monitoring for the first 30 days post-launch (compliance, reliability, adoption, and operational metrics).

Complications (Realistic Curveballs)

1. Week 4: The Security team flags that Atlas’s audit log can be edited by admin users via an undocumented support endpoint. The vendor offers a fix, but the ETA is 6–8 weeks.
2. Week 7: A key validation engineer is pulled into an urgent remediation for an unrelated internal audit finding, reducing validation capacity by 50% for 3 weeks.
3. Week 9: Clinical Ops escalates that a CRO partner cannot use Okta and needs access within 2 weeks for study startup; Quality insists partner access must be least-privilege with full traceability.

Interview Prompt

Walk through how you would execute this program end-to-end. Be explicit about trade-offs: what you would ship in 120 days to meet Part 11 expectations, what you would defer, and what evidence you would produce to withstand an FDA inspection. Assume you are accountable for schedule, cross-functional alignment, and audit readiness.